Clinical Reviews in Allergy & Immunology

, Volume 42, Issue 2, pp 164–171 | Cite as

Immunology, Autoimmunity, and Autoantibodies in Parkinson’s Disease

  • Michal Benkler
  • Nancy Agmon-Levin
  • Sharon Hassin-Baer
  • Oren S. Cohen
  • Oscar-Danilo Ortega-Hernandez
  • Amalia Levy
  • Samuel-Datum Moscavitch
  • Martine Szyper-Kravitz
  • Maya Damianovich
  • Miri Blank
  • Joab Chapman
  • Yehuda Shoenfeld


Recent revelations of immune alterations in Parkinson’s disease have led to the convergence that an autoimmune mechanism may play a role in the etiopathogenesis of this neurodegenerative disease. In the current study, 77 Parkinson’s disease patients and 77 matched healthy controls were analyzed for the presence of seven autoantibodies previously found to be associated with central nervous system manifestations namely: antineuronal-cells, anti-brain lysate, anti-dsDNA, anti-phosphatidylserine, anti-cardiolipin, anti-serotonin, and anti-melanocytes antibodies. Patients underwent systematic assessments of demographics, clinical, and biochemical manifestations. Three autoantibodies were found to be more prevalent among Parkinson’s disease patients (antineuronal cells10.3% vs. 1.3%, p = 0.017; anti-brain lysate 9.1% vs. 1.3%, p = 0.032; anti-dsDNA 10.3% vs. 2.6%, p = 0.049). Clinical manifestations of Parkinson’s disease, particularly dyskinesia and depression, were found to be associated with the presence of these autoantibodies.


Parkinson’s disease Autoimmune Autoantibodies Dyskinesia Depression 


  1. 1.
    Nussbaum RL, Ellis CE (2003) Alzheimer’s disease and Parkinson disease. N Engl J Med 348:1356–1364PubMedCrossRefGoogle Scholar
  2. 2.
    Israel Z, Hassin-Bear S (2005) Subthalamic stimulation for Parkinson’s disease. IMAJ 7:458–463PubMedGoogle Scholar
  3. 3.
    Crossman AR (2000) Functional anatomy of movement disorders. J Anat 196:519–525PubMedCrossRefGoogle Scholar
  4. 4.
    Lerler A, Bagic A (2008) Olfactory pathogenesis of idiopathic Parkinson disease revisited. Mov Disord 23:1076–1084CrossRefGoogle Scholar
  5. 5.
    Benkler M, Agmon-Levin N, Shoenfeld Y (2009) Parkinson’s disease, autoimmunity, and olfaction. Int J Neurosci 119:2133–2143PubMedCrossRefGoogle Scholar
  6. 6.
    Shoenfeld Y, Blank M, Abu-Shakra M et al (2008) The mosaic of autoimmunity: prediction, autoantibodies and therapy in autoimmune disease. IMAJ 10:13–19PubMedGoogle Scholar
  7. 7.
    Møller A, Perrild H, Pedersen H, Høier-Madsen M (1989) Parkinson’s disease and autoimmunity. Acta Neurol Scand 79:173–175PubMedCrossRefGoogle Scholar
  8. 8.
    Liu B, Gao HM, Hong JS (2003) Parkinson’s disease and exposure to infectious agents and pesticides and the occurrence of brain injury: role of neuroinflammation. Environ Health Perspect 111:1065–1073PubMedCrossRefGoogle Scholar
  9. 9.
    Fiszer U, Mix E, Fredrikson S, Kostulas V, Olsson T, Link H (1994) Gamma delta+T cells are increased in patients with Parkinson’s disease. J Neurol Sci 121:39–45PubMedCrossRefGoogle Scholar
  10. 10.
    Papachroni KK, Ninkina N, Papapanagiotou A et al (2007) Autoantibodies to alpha-synuclein in inherited Parkinson’s disease. J Neurochem 101:749–756PubMedCrossRefGoogle Scholar
  11. 11.
    Zappia M, Crescibene L, Bosco D et al (2002) Anti-GM1 ganglioside antibodies in Parkinson’s disease. Acta Neurol Scand 106:54–57PubMedCrossRefGoogle Scholar
  12. 12.
    Carvey PM, McRae A, Lint TF et al (1991) The potential use of dopamine neuron antibody and a striatal-derived neurotropic factor as diagnostic markers in Parkinson’s disease. Neurology 41:53–58PubMedGoogle Scholar
  13. 13.
    Le WD, Rowe DB, Jankovic J, Xei W, Apple SH (1999) Effects of cerebrospinal fluid from patients with Parkinson disease on dopaminergic cells. Arch Neurol 56:194–200PubMedCrossRefGoogle Scholar
  14. 14.
    Orr CF, Rowe DB, Mizuno Y, Mori H, Halliday GM (2005) A possible role of humoral immunity in the pathogenesis of Parkinson’s disease. Brain 128:2665–2674PubMedCrossRefGoogle Scholar
  15. 15.
    Chen S, Le WD, Xie WJ et al (1998) Experimental destruction of substantia nigra initiated by Parkinson disease immunoglobulins. Arch Neurol 55:1075–1080PubMedCrossRefGoogle Scholar
  16. 16.
    He Y, Le WD, Appel SH (2002) Role of FCγ receptors in nigral cell injury induced by Parkinson’s disease immunoglobulin injection into mouse substantia nigra. Exp Neurol 176:322–327PubMedCrossRefGoogle Scholar
  17. 17.
    Al-Fulaij MA, Ren Y, Beinborn M, Kopin AS (2008) Pharmacological analysis of human D1 and D2 dopamine receptor missense variants. J Mol Neurosci 34:211–223PubMedCrossRefGoogle Scholar
  18. 18.
    Abramsky O, Litvin Y (1978) Autoimmune response to dopamine-receptor as a possible mechanism in the pathogenesis of Parkinson’s disease and schizophrenia. Perspect Biol Med 22:104–114PubMedGoogle Scholar
  19. 19.
    Luedtke RR, Griffin SA, Conroy SS, Jin X, Pinto A, Sesack SR (1999) Immunoblot and immunohistochemical comparison of murine monoclonal antibodies specific for the rat D1a and D1b dopamine receptor subtypes. J Neuroimmunol 101:170–187PubMedCrossRefGoogle Scholar
  20. 20.
    Farooqui SM, Brock JW, Hamdi A, Prasad C (1991) Antibodies against synthetic peptides predicted from the nucleotide sequence of D2 receptor recognize native dopamine receptor protein in rat striatum. J Neurochem 57:1363–1369PubMedCrossRefGoogle Scholar
  21. 21.
    Boundy VA, Luedtke RR, Artymyshyn RP, Filtz TM, Molinoff PB (1993) Development of polyclonal anti-D2 dopamine receptor antibodies using sequence-specific peptides. Mol Pharmacol 43:666–676PubMedGoogle Scholar
  22. 22.
    Johnston JM, Wood DF, James JD, Johanston DG (1992) Preparation and characterization of an antibody specific to the rat dopamine D2 receptor. J Endocrinol 134:227–233PubMedCrossRefGoogle Scholar
  23. 23.
    Myers PR, Donlon M, McCarthy K, Livengood D, Shain W (1976) Evidence for a dopamine receptor antibody. Biochem Biophys Res Commun 72:1311–1318PubMedCrossRefGoogle Scholar
  24. 24.
    Agmon-Levin N, Shaye K, Shoenfeld Y (2009) Neuropsychiatric manifestations of systemic lupus erythematosus—a primary disease manifestation. J Neuroimmunol 207:1–2PubMedCrossRefGoogle Scholar
  25. 25.
    Gualtierotti R, Biggioggero M, Penatti AE, Meroni PL (2010) Updating on the pathogenesis of systemic lupus erythematosus. Autoimmun Rev 10:3–7PubMedCrossRefGoogle Scholar
  26. 26.
    Briani C, Lucchetta M, Ghirardello A et al (2009) Neurolupus is associated with anti-ribosomal P protein antibodies: an inception cohort study. J Autoimmun 32:79–84PubMedCrossRefGoogle Scholar
  27. 27.
    Sakic B, Kirkham DL, Ballok DA et al (2005) Proliferating brain cells are a target of neurotoxic CSF in systemic autoimmune disease. J Neuroimmunol 169:68–85PubMedCrossRefGoogle Scholar
  28. 28.
    Zandman-Goddard G, Chapman J, Shoenfeld Y (2007) Autoantibodies involved in neuropsychiatric SLE and antiphospholipid syndrome. Semin Arthritis Rheum 36:297–315PubMedCrossRefGoogle Scholar
  29. 29.
    Tobón GJ, Alard JE, Youinou P, Jamin C (2009) Are autoantibodies triggering endothelial cell apoptosis really pathogenic? Autoimmun Rev 8:605–610PubMedCrossRefGoogle Scholar
  30. 30.
    Zandman-Goddard G, Blank M, Langevitz P et al (2005) Anti-serum amyloid component P antibodies in patients with systemic lupus erythematosus correlate with disease activity. Ann Rheum Dis 64:1698–1702PubMedCrossRefGoogle Scholar
  31. 31.
    Morer A, Lázaro L, Sabater L, Massana J, Castro J, Graus F (2008) Antineuronal antibodies in a group of children with obsessive—compulsive disorder and Tourette syndrome. J Psychiatr Res 42:64–68PubMedCrossRefGoogle Scholar
  32. 32.
    Yeh CB, Wu CH, Tsung HC, Chen CW, Shyu JF, Leckman JF (2005) Antineural antibody in patients with Tourette’s syndrome and their family members. J Biomed Sci 13:101–112PubMedCrossRefGoogle Scholar
  33. 33.
    Van de Warrenburg BP, Church AJ, Martino D et al (2008) Antineuronal antibodies in Parkinson’s disease. Mov Disord 23:958–963PubMedCrossRefGoogle Scholar
  34. 34.
    Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55:181–184PubMedCrossRefGoogle Scholar
  35. 35.
    WMA Medical Ethics Committee. Updating the WMA Declaration of Helsinki. Wld Med J 1999 45:11–13Google Scholar
  36. 36.
    York NR, Mendoza JP, Ortega SB et al (2010) Immune regulatory CNS-reactive CD8+T cells in experimental autoimmune encephalomyelitis. J Autoimmun 35:33–44PubMedCrossRefGoogle Scholar
  37. 37.
    Kotby AA, El Badawy N, El Sokkary S, Moawad H, El Shawarby M (1998) Antineuronal antibodies in rheumatic chorea. Clin Diagn Lab Immunol 5:836–839PubMedGoogle Scholar
  38. 38.
    Smith PP, Gordon C (2010) Systemic lupus erythematosus: clinical presentations. Autoimmun Rev 10:43–45PubMedCrossRefGoogle Scholar
  39. 39.
    Hadjivassiliou M, Aeschlimann P, Strigun A, Sanders DS, Woodroofe N, Aeschlimann D (2008) Autoantibodies in gluten ataxia recognize a novel neuronal transglutaminase. Ann Neurol 64:332–343PubMedCrossRefGoogle Scholar
  40. 40.
    Hadjivassiliou M, Boscolo S, Tongiorgi E et al (2008) Cerebellar ataxia as a possible organ-specific autoimmune disease. Mov Disord 23:1370–1377PubMedCrossRefGoogle Scholar
  41. 41.
    Katzav A, Ben-Ziv T, Chapman J, Blank M, Reichlin M, Shoenfeld Y (2008) Anti-P ribosomal antibodies induce defect in smell capability in a model of CNS -SLE (depression). J Autoimmun 21:393–398CrossRefGoogle Scholar
  42. 42.
    Agmon-Levin N, Gilburd B, Kivity S et al (2009) Anti-ribosomal-P antibodies in lupus patients and healthy controls: evaluation of three ELISA assays. IMAJ 11:403–406PubMedGoogle Scholar
  43. 43.
    Shoenfeld Y (2007) To smell autoimmunity: anti-P-ribosomal autoantibodies, depression, and the olfactory system. J Autoimmun 28:165–169PubMedCrossRefGoogle Scholar
  44. 44.
    Katzav A, Solodeev I, Brodsky O et al (2007) Induction of autoimmune depression in mice by anti-ribosomal P antibodies via the limbic system. Arthritis Rheom 56:938–948CrossRefGoogle Scholar
  45. 45.
    Toubi E, Shoenfeld Y (2007) Clinical and biological aspects of anti-P-ribosomal protein autoantibodies. Autoimmun Rev 6:119–125PubMedCrossRefGoogle Scholar
  46. 46.
    Gao HX, Campbell SR, Cui MH et al (2009) Depression is an early disease manifestation in lupus-prone MRL/lpr mice. J Neuroimmunol 207:45–56PubMedCrossRefGoogle Scholar
  47. 47.
    Moscavitch SD, Szyper-Kravitz M, Shoenfeld Y (2009) Autoimmune pathology accounts for common manifestations in a wide range of neuro-psychiatric disorders: the olfactory and immune system interrelationship. Clin Immunobiol 130:235–243CrossRefGoogle Scholar
  48. 48.
    Fünfgeld EW, Baggen M, Nedwidek P, Richstein B, Mistlberger G (1989) Double-blind study with phosphatidylserine (PS) in parkinsonian patients with senile dementia of Alzheimer’s type (SDAT). Prog Clin Biol Res 317:1235–1246PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Michal Benkler
    • 1
    • 2
  • Nancy Agmon-Levin
    • 2
    • 3
  • Sharon Hassin-Baer
    • 4
    • 7
  • Oren S. Cohen
    • 4
    • 7
  • Oscar-Danilo Ortega-Hernandez
    • 2
  • Amalia Levy
    • 5
  • Samuel-Datum Moscavitch
    • 2
  • Martine Szyper-Kravitz
    • 2
    • 3
  • Maya Damianovich
    • 2
  • Miri Blank
    • 2
    • 3
  • Joab Chapman
    • 4
    • 7
  • Yehuda Shoenfeld
    • 2
    • 3
    • 6
    • 7
    • 8
  1. 1.Faculty of Health Sciences, Medical SchoolBen-Gurion University of the NegevBeer-ShebaIsrael
  2. 2.The Zabludowicz Center for Autoimmune DiseasesSheba Medical CenterTel HashomerIsrael
  3. 3.Department of Medicine ‘B’Sheba Medical CenterTel HashomerIsrael
  4. 4.Parkinson Disease and Movement Disorders Clinic, Department of Neurology and Sagol Neuroscience CenterSheba Medical CenterTel HashomerIsrael
  5. 5.Department of Epidemiology and Health Services Evaluation, Faculty of Health SciencesBen-Gurion University of the NegevBeer-ShebaIsrael
  6. 6.Incumbent of the Laura Schwarz-Kip Chair for Research of Autoimmune DiseasesTel-Aviv UniversityTel-AvivIsrael
  7. 7.Sackler Faculty of MedicineTel-Aviv UniversityTel-AvivIsrael
  8. 8.Department of Medicine ‘B’ & Center for Autoimmune DiseasesChaim Sheba Medical CenterTel-HashomerIsrael

Personalised recommendations